Introduction: Chronic kidney disease is characterized by a progressive deterioration of renal function. At the end of the progression, when complications occur (overhydration, electrolyte imbalances or retention of uremic toxins), a percentage of patients requiring renal replacement therapy (haemodialysis). When starting the haemodialysis, the patient holds the residual renal function (RRF) which is lost over time. To preserve the RRF, the patient is treated with diuretics loops and / or thiazide diuretics. The effect of this treatment is lost when renal function worsens. In this context, there are few studies that explore the use and effectiveness of diuretics in patients on haemodialysis 2. Objectives and Hypothesis:
Hypothesis: The treatment with furosemide and hydrochlorothiazide in haemodialysis patients with RRF could:
- To decrease in weight gain between haemodialysis sessions.
- To increase urine volume.
- To decrease the ultrafiltration in haemodialysis sessions ( the long interdialytic interval)
Main Objective:To asses the effect of combined hydrochlorothiazide-furosemide therapy on gain weight between haemodialysis sessions in patients with RRF
Secondary Objective: To asses the effect of combined hydrochlorothiazide-furosemide therapy on dialytic, clinical and analytical variables and use of the antihypertensive treatment
3. Methodology: Randomized open clinical trial to compare the effectiveness of the administration of diuretics in haemodialysis patients with residual renal function in single centre.
The population of study are patients with chronic renal disease in haemodialysis therapy that they preserve residual renal function ( more 200ml daily of urine). It will be a simple randomization, to asses the effect of combined hydrochlorothiazide-furosemide therapy
After a of 15 days washout without diuretic treatment, patients will be randomized to receive or not receive combined diuretic treatment for 1 month. After a 1 month washout , the patients will be receive or not the treatment according to cross over trial.
Full Title of Study: “Randomized Open Clinical Trial to Compare the Effectiveness of the Administration of Diuretics in Hemodialysis Patients With Residual Renal Function in Single Centre”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: March 2015
- Drug: Hydrochlorothiazide and furosemide
- This clinical trial is cross-over study. The diuretic arm’s patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
Arms, Groups and Cohorts
- Experimental: Diuretics arm
- The diuretic arm’s patients will receive combined thiazide-furosemide therapy for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
- No Intervention: Control Arm
Clinical Trial Outcome Measures
- To asses the effect of combined hydrochlorothiazide-furosemide therapy on weight gain between haemodialysis sessions in patients with RRF
- Time Frame: 14 weeks
- Gain weight
- To asses the effect of combined hydrochlorothiazide-furosemide therapy on dialytic, clinical and analytical variables and use of the antihypertensive treatment
- Time Frame: 14 weeks
- Variations of the next parameters in the different periods(15 days, 1, 2 and 3 months) of the clinical trial: urine volume, reduction of ultrafiltration in interdialysis sessions and long interdialytic interval, dry weight, blood pressure intradialysis,plasma potassium, plasma bicarbonate, plasma uric acid, urinary sodium, urinary chloro and urinary potassium in interdialytic sessions . Use of the antihypertensive treatment. To Appear complications for example: hypotensions, cramps and symptomatic hyperuricemia. Creatinine clearance and urea clearance. Use of potassium treatment intradialysis.
Participating in This Clinical Trial
- Over 18 years
- Chronic kidney disease, stage 5 Chronic Kidney Disease, in haemodialysis
- Renal residual function preserved(more or equal 200 ml daily of urine)
- Minimum 3 months on haemodialysis and wish to participate in this study
- Less 4 millequivalent of potassium plasma in interdialytic sessions or to require potassium intradialytic treatment.
- Less 1 Kg of gain weight in the long interdialytic interval.
- Adverse effects with treatment in the past.
- To refusal to participate in the study.
- Pregnancy or lactation period.
- Contraindication the use of diuretic therapy, according to pharmacological profile.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 90 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Corporacion Parc Tauli
- Provider of Information About this Clinical Study
- Principal Investigator: Maria Isabel Bolós Contador, Medica Doctor – Corporacion Parc Tauli
- Overall Official(s)
- Mabel – Bolos-Contador, MD, Principal Investigator, Corporacion Parc Tauli
- Overall Contact(s)
- Mabel – Bolos-Contador, MD, 0034 937231010, firstname.lastname@example.org
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.